Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879899 | 0.84 | EPHX1 (0.54) | AKR1C3AKR1C2LMNAPSIP1GAA | |
| SCHEMBL16799901 | 0.82 | PTGS1 (0.50) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL13723847 | 0.81 | AKR1C3 (0.70) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL168255 | 0.81 | HPGD (0.44) | PTGS2PTGS1PSIP1GAAMT-CO2 | |
| SCHEMBL12465947 | 0.81 | KMT2A (0.47) | PTGS2LMNAPSIP1GAA | |
| SCHEMBL168108 | 0.80 | PSIP1 (0.48) | PTGS1AKR1C3AKR1C2PSIP1GAA | |
| SCHEMBL28234635 | 0.80 | RORC (0.50) | CYP2C9PSIP1GAA | |
| SCHEMBL29280844 | 0.80 | RORC (0.50) | CYP2C9PSIP1GAA | |
| SCHEMBL59197 | 0.79 | PTGS2 (0.74) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL1758657 | 0.79 | AKR1C3 (0.54) | PTGS2PTGS1AKR1C3AKR1C2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI LITEDD CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-4039674-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Litedd Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| CN-114502532-A | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-105980353-B | ROR gamma modulators | 领先制药控股公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| EP-3077372-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Cel Models IP B.V. (NL) | 2016-10-12 | — | — | EP | disclosed |
| CN-105980353-A | ROR gamma modulators | 领先制药CEL模型知识产权公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2015082533-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2015-06-11 | — | — | WO | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012100732-A1 | RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS, COMPOSITION CONTAINING THEM AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012028100-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028100-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RORB, RORA, RORC | PTGS2 4301/4885PTGS1 3599/4885AKR1C3 321/4885 |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | RORC, RORA, RORB | PTGS2 4258/4885PTGS1 3026/4885AKR1C3 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.